Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22624889 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1ALDH1A1RAB9AKDM4E | |
| SCHEMBL13562522 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1ALDH1A1RAB9AKDM4E | |
| SCHEMBL12123908 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1ALDH1A1RAB9AKDM4E | |
| SCHEMBL30173758 | 0.82 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1ALDH1A1RAB9AKDM4E | |
| SCHEMBL5463532 | 0.82 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1ALDH1A1RAB9AKDM4E | |
| SCHEMBL23782350 | 0.82 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1ALDH1A1RAB9AKDM4E | |
| SCHEMBL12123748 | 0.81 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1ALDH1A1RAB9AKDM4E | |
| Hydrochloric Acid SCHEMBL4922813 | 0.81 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1ALDH1A1RAB9AKDM4E | |
| SCHEMBL12123752 | 0.81 | ACHE (0.67) | SMN1; SMN2NPC1ALDH1A1RAB9AKDM4E | |
| SCHEMBL22624965 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1ALDH1A1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150290200-A1 | INTRACELLULAR KINASE INHIBITORS | PHARMACYCLICS INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150290200-A1 | INTRACELLULAR KINASE INHIBITORS | PHARMACYCLICS INC (US) | 2015-10-15 | — | — | US | disclosed |
| EP-2865381-A1 | ITK inhibitors for treating blood cell malignancies | Pharmacyclics, Inc. (US) | 2015-04-29 | — | — | EP | disclosed |
| US-20140080833-A1 | INTRACELLULAR KINASE INHIBITORS | MANNKIND CORPORATION (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080833-A1 | INTRACELLULAR KINASE INHIBITORS | MANNKIND CORPORATION (US) | 2014-03-20 | — | — | US | disclosed |
| US-20110281850-A1 | INTRACELLULAR KINASE INHIBITORS | MANNKIND CORPORATION (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281850-A1 | INTRACELLULAR KINASE INHIBITORS | MANNKIND CORPORATION (US) | 2011-11-17 | — | — | US | disclosed |
| US-20070293499-A1 | Intracellular Kinase Inhibitors | MANNKIND CORPORATION (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293499-A1 | Intracellular Kinase Inhibitors | MANNKIND CORPORATION (US) | 2007-12-20 | — | — | US | disclosed |
| WO-2007136790-A2 | INTRACELLULAR KINASE INHIBITORS | MANNKIND CORPORATION (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293499-A1 | Intracellular Kinase Inhibitors | PI4KB, BTK, LTK | SMN1; SMN2 4304/4885NPC1 3708/4885ALDH1A1 4370/4885 |
| US-20150290200-A1 | INTRACELLULAR KINASE INHIBITORS | PI4KB, BTK, LTK | SMN1; SMN2 4304/4885NPC1 3708/4885ALDH1A1 4370/4885 |
| US-20110281850-A1 | INTRACELLULAR KINASE INHIBITORS | PI4KB, BTK, LTK | SMN1; SMN2 4304/4885NPC1 3708/4885ALDH1A1 4370/4885 |
| US-20140080833-A1 | INTRACELLULAR KINASE INHIBITORS | PI4KB, BTK, LTK | SMN1; SMN2 4304/4885NPC1 3708/4885ALDH1A1 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.